Page 13 - Systemic Sclerosis News Today

Cumberland Pharmaceuticals Reports First Quarter 2021 Financial Results & Company Update News provided by Share this article NASHVILLE, Tenn., May 11, 2021 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and first quarter 2021 financial results. Net revenues from continuing operations during the quarter were $10.5 million, a 26.5% increase over the prior year period. The company also recorded an additional...

The Autoimmune Registry announces the "Cure the Mothers Disease" Fundraiser News provided by Share this article Share this article NEW HAVEN, Conn., May 5, 2021 The Autoimmune Registry (ARI) announces its "Cure the Mothers Disease" fundraiser to support research on innovative diagnostic tools being developed at the University of Kentucky.  Sydney Abend, a mother with Sjogrens Syndrome, told ARI, "For 10 years, I was told everyone has dry eyes and youre just getting old. I felt validated when...

Share this article Share this article TEL-AVIV, Israel, April 26, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced enrollment of the first patient in its Phase 2a study of CM-101 in Non-Alcoholic Steatohepatitis (NASH). CM-101 is a first-in-class humanized monoclonal antibody designed to bind to and block CCL24 ...

(0) NEW YORK, NY / ACCESSWIRE / April 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the first patient has been dosed in an open-label Phase 2 clinical trial of belumosudil, the Companys ROCK2 inhibitor, in patients with diffuse cutaneous systemic sclerosis (dcSSc), a chronic immune disorder characterized by fibrosis of the skin and internal organs. The Phase 2 study (KD025-215) will enroll up to 15 adults with dcSSc who will receive orally administered belumosudil 200 mg tw...

Chemomab Completes Merger with Anchiano Therapeutics USA - English Combined company will focus on advancing Chemomabs CM-101 currently in Phase 2 for rare fibrotic indications Company to receive gross proceeds of $45.5 Million from a PIPE financing, led by healthcare-focused investors Cormorant Asset Management, OrbiMed, Peter Thiel and Christian Angermayers Presight Capital and Apeiron Investment Group News provided by Share this article Share this article TEL-AVIV, Israel, March. 16, 2021 /PR...

Cumberland Pharmaceuticals Reports 9% Revenue Growth In 2020 News provided by Share this article NASHVILLE, Tenn., March 9, 2021 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology and rheumatology, today announced fourth quarter and full year 2020 financial results. Net Revenues for the fourth quarter were $10.3 million, up 10% over the prior year period. For the full year 2020, Net Revenues total...

Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2020 Financial Results News provided by Share this article NASHVILLE, Tenn., March 2, 2021 /PRNewswire/ --  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2020 financial results and Company update after the market closes on Tuesday, Mar. 9, 2021. A conference call and live internet webcast will be held on Tuesday, March 9, 2021, at 4:30 p.m. Eastern Time to discuss th...

CiVi Biopharma to Participate in HC Wainwright BioConnect 2021 Conference News provided by Share this article CHEVY CHASE, Md., Jan. 8, 2021 /PRNewswire/ --  CiVi Biopharma, Inc. ("CiVi" or "the Company"), a privately held company focused on creating novel therapies against diseases where the unmet medical need exists, today announces that Company management will participate in the upcoming HC Wainwright BioConnect 2021 Conference taking place virtually from January 11-14, 2021.  Shalom Jaco...

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare...

Published: Dec 16, 2020 By Joseph Constance A healthy immune system defends the body against disease and other conditions. However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Autoimmune disease impacts different parts of the body, weakening functionality. It may be life-threatening. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. The more common autoimmune diseas...